A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2
Annals of Internal Medicine · 2024
DOI: 10.7326/m23-2593 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of Internal Medicine, 2024. Verfasst von Catharine I Paules und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania (C.I.P.). Hauptthemen laut MEDLINE: Azetidines, COVID-19, Purines, Pyrazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania (C.I.P.).
- Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland (J.W., T.B.).
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (K.M.T., K.S., R.T.D., L.E.D., G.A.D., S.U.N., J.V., G.E.P.).
- Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia (V.C.M.).
- National Centre for Infectious Diseases, Tan Tock Seng Hospital, Yong Loo Lin School of Medicine, and Lee Kong Chian School of Medicine, Singapore (D.C.L.).
- Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California (O.O.Y.).
ORCID-Profile: Catharine I Paules, Kay M Tomashek, Tyler Bonnett, Kanal Singh, Vincent C Marconi, Richard T Davey, David C Lye, Otto O Yang, Constance A Benson, Gregory A Deye, Sarah B Doernberg, Noreen A Hynes, Robert Grossberg, Cameron R Wolfe, William R Short, Gail E Potter
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Paules, C. I., Wang, J., Tomashek, K. M., Bonnett, T., Singh, K., Marconi, V. C., Davey, R. T., Lye, D. C., Dodd, L. E., Yang, O. O., Benson, C. A., Deye, G. A., Doernberg, S. B., Hynes, N. A., Grossberg, R., Wolfe, C. R., Nayak, S. U., Short, W. R., Voell, J., …, & Rapaka, R. R. (2024). A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. Annals of Internal Medicine. https://doi.org/10.7326/m23-2593
Vancouver
Paules CI, Wang J, Tomashek KM, Bonnett T, Singh K, Marconi VC, et al. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. Annals of Internal Medicine. 2024. doi:10.7326/m23-2593
BibTeX
@article{Paules2024,
author = {Paules, Catharine I and Wang, Jing and Tomashek, Kay M and Bonnett, Tyler and Singh, Kanal and Marconi, Vincent C and Davey, Richard T and Lye, David C and Dodd, Lori E and Yang, Otto O and Benson, Constance A and Deye, Gregory A and Doernberg, Sarah B and Hynes, Noreen A and Grossberg, Robert and Wolfe, Cameron R and Nayak, Seema U and Short, William R and Voell, Jocelyn and Potter, Gail E and Rapaka, Rekha R},
title = {A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2},
journal = {Annals of Internal Medicine},
year = {2024},
doi = {10.7326/m23-2593}
}
EUVIMED